Dataset Information

Detection of Five Solid Carcinomas Using Blood Circulating Proteins

ABSTRACT: When diagnosed in a metastatic stage cancer is mostly incurable making its early detection via biomarkers of immense clinical interest. Proteins circulating in blood are a preferred source of biomarkers for a wide range of cancers due to the ease and non-invasiveness of collection. Our approach to cancer biomarker discovery is based on the observation that proteomic changes in tumor tissue are remotely detectable as changes in the protein composition of blood plasma. To determine whether these changes in the plasma of patients are specific for their specific cancer or represent a response to cancer in general we performed a cross-tumor plasma proteomic study. Using a proteomic serum/plasma workflow consisting of the combined use of N-glycosite enrichment and SWATH mass spectrometry (SWATH-MS), we investigated 155 blood samples derived from cohorts of patients with carcinomas at a localized or locally advanced clinical stage, or from a matched control group. A quantitative comparison of the resulting N-glycosite profiles indicated that some biomarkers are common to several cancers, while others are highly specific for one cancer type.

INSTRUMENT(S): TripleTOF 5600

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma, Blood Serum

DISEASE(S): Lung Cancer,Prostate Adenocarcinoma,Colon Cancer,Pancreatic Cancer,Malignant Neoplasm Of Ovary

SUBMITTER: Tatjana Sajic

LAB HEAD: Ruedi Aebersold

PROVIDER: PXD004998 | Pride | 2018-08-09

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	CrossTumourStudy_sample_annotataion.txt	Txt
	DDA_files.txt	Txt
	LibrarySWATH_Nglyco_plasma.TraML	Other
	Panc_sample_annotataion_ValidationExp_2017.txt	Txt
	Proc_sample_annotataion_ValidExp_2017.txt	Txt

Items per page:

1 - 5 of 707

Publications

Similarities and Differences of Blood N-Glycoproteins in Five Solid Carcinomas at Localized Clinical Stage Analyzed by SWATH-MS.

Sajic Tatjana T Liu Yansheng Y Arvaniti Eirini E Surinova Silvia S Williams Evan G EG Schiess Ralph R Hüttenhain Ruth R Sethi Atul A Pan Sheng S Brentnall Teresa A TA Chen Ru R Blattmann Peter P Friedrich Betty B Niméus Emma E Malander Susanne S Omlin Aurelius A Gillessen Silke S Claassen Manfred M Aebersold Ruedi R

Cell reports 20180501 9

Cancer is mostly incurable when diagnosed at a metastatic stage, making its early detection via blood proteins of immense clinical interest. Proteomic changes in tumor tissue may lead to changes detectable in the protein composition of circulating blood plasma. Using a proteomic workflow combining N-glycosite enrichment and SWATH mass spectrometry, we generate a data resource of 284 blood samples derived from patients with different types of localized-stage carcinomas and from matched controls. ...[more]

PMID: 29847809

Similar Datasets

Project description:Ovarian cancer is one of the most common cancer among women in the world, and chemotherapy remains the principal treatment for patients. However, drug resistance is a major obstacle to the effective treatment of ovarian cancers and the underlying mechanism is not clear. An increased understanding of the mechanisms that underline the pathogenesis of drug resistance is therefore needed to develop novel therapeutics and diagnostic. Herein, we report the comparative analysis of the doxorubicin sensitive OVCAR8 cells and its doxorubicin-resistant variant NCI/ADR-RES cells using integrated global proteomics and N-glycoproteomics. A total of 1525 unique N-glycosite-containing peptides from 740 N-glycoproteins were identified and quantified, of which 253 N-glycosite-containing peptides showed significant change in the NCI/ADR-RES cells. Meanwhile, stable isotope labeling by amino acids in cell culture (SILAC) based comparative proteomic analysis of the two ovarian cancer cells led to the quantification of 5509 proteins. As about 50% of the identified N-glycoproteins are low-abundance membrane proteins, only 44% of quantified unique N-glycosite-containing peptides had corresponding protein expression ratios. The comparison and calibration of the N-glycoproteome versus the proteome classified 14 change patterns of N-glycosite-containing peptides, including 8 up-regulated N-glycosite-containing peptides with the increased glycosylation sites occupancy, 35 up-regulated N-glycosite-containing peptides with the unchanged glycosylation sites occupancy, 2 down-regulated N-glycosite-containing peptides with the decreased glycosylation sites occupancy, 46 down-regulated N-glycosite-containing peptides with the unchanged glycosylation sites occupancy. Integrated proteomic and N-glycoproteomic analyses provide new insights, which can help to unravel the relationship of N-glycosylation and multidrug resistance (MDR), understand the mechanism of MDR, and discover the new diagnostic and therapeutic targets.